A study by Zhang et al. in this issue of Neuron reveals a novel mechanism of control of vestibular motor functions by the orexin (hypocretin) system in the perifornical/LH area through the lateral vestibular nucleus in the brainstem. This knowledge provides new insights into the understanding of brain circuitry that controls motor functions and diseases/conditions related to impairments in this circuitry.
A study by Zhang et al. in this issue of Neuron reveals a novel mechanism of control of vestibular motor functions by the orexin (hypocretin) system in the perifornical/LH area through the lateral vestibular nucleus in the brainstem. This knowledge provides new insights into the understanding of brain circuitry that controls motor functions and diseases/conditions related to impairments in this circuitry.
The orexin (hypocretin) system in the lateral hypothalamic (LH)/perifornical area participates in many critical brain functions including energy and sleep homeostasis, drug addiction, stress response, and sensorimotor integration (Tsujino and Sakurai, 2009) . It is well established that the loss of orexin-synthesizing neurons or orexin receptors leads to narcolepsy in humans and animals (Ritchie et al., 2010) . Further information is emerging as to how this loss leads to the transition from wakefulness to sleep during an episode of narcolepsy (Ritchie et al., 2010) . However, it is still not known how the lack of a functioning orexin system leads to cataplexy or loss of muscle tone when an episode of narcolepsy hits (Scammell et al., 2009) .
In an elegant study in this issue of Neuron, Zhang et al. (2011) demonstrate an interesting and novel role of the orexin system in the regulation of motor functions in the brains of rats, which may help explain the loss of muscle tone (i.e., cataplexy) in narcolepsy. The authors present a convincing case of how the neuropeptide orexin regulates motor function through a vestibular center in the brain, the lateral vestibular nucleus (LVN) in rats. First, by using quantitative RT-PCR and immunocytochemistry, the authors demonstrate the expression of OX 1 and OX 2 receptors (hypocretin receptors 1 and 2) in the LVN, specifically in the giant Deiters' neurons in this nucleus. These results are consistent with previous reports of the innervation of the vestibular nuclei in rats by orexincontaining nerve fibers (Cutler et al., 1999; Peyron et al., 1998 These data are consistent with reports of direct excitatory effects of orexin on postsynaptic neurons in other brain areas (Wu et al., 2002 (Wu et al., , 2004 . The consequence of the inward current on LVN neurons is to directly excite them. The application of orexin-A induced a significant depolarization and increase in the firing rate of the LVN neurons. Orexin-A facilitated the generation of action potentials (APs) by reducing the latency of induction of APs and increasing the instantaneous firing rate. Based on these cellular studies, the authors reasoned that orexin fibers that innervate the LVN should exert physiological functions in the regulation of vestibular motor behaviors. A remarkable array of in vivo electrophysiological and behavioral testing was then designed to examine this hypothesis: first, in urethane-anesthetized rats, a microinjection of orexin-A into the LVN excited LVN neurons with a short latency. Next, rats given a unilateral microinjection of orexin-A into the LVN showed a significant increase in the rotation to the contralateral direction of the injection side as compared with rats that received vehicle injection or those that were sham operated upon, suggesting that infusion of orexin-A into the LVN induces changes in static posture. In addition, bilateral infusion of orexin-A into the LVN significantly reduced the traverse time in the horizontal balance beam test and the time required for rats to turn 180 to an upward position from the initial downward position in the negative geotaxis test, suggesting that the application of orexin into the LVN promotes dynamic postural changes in animals. Finally and most intriguingly, the infusion of orexin-A receptor antagonist SB334867 neither inhibited basal firing of LVN neurons nor blocked rat motor performance in either the horizontal balance beam or negative geotaxis tests. Rather, this treatment significantly compromised behaviors depending on the motor challenge. In rats treated with SB334867, the time required to traverse an inclined balance beam significantly increased as compared with sham or vehicle groups. In an accelerating rota-rod test, the infusion significantly decreased the time that rats stayed on the accelerating rota-rod. These data indicate that endogenous orexin is required in the central control of motor functions in animals.
All together, the results presented in this study are clearcut and self-evident but leave some unanswered questions. For instance, it is not clear why the orexin-A receptor antagonist SB334867 induced such significanteffects in behavioral testing, but why only partial inhibition of orexin-A-induced effects in LVN neurons in brain slices. This discrepancy may be due to differential effects of SB334867 under in vitro versus in vivo conditions. It is not shown whether LVN neurons were in fact activated by the microinjection of orexin-A into the LVN. Except for the readout of behavioral changes, no other evidence was provided in the same experiments that would indicate the activation of LVN neurons (e.g., the detection of c-fos expression) by orexin-A. And related to this question, it is not clear to what extent the inhibition of LVN neurons by SB334867 can lead to the alterations in motor functions reported in these animals. Also, this study does not address whether changes occur in the levels of orexin in the LVN during the time that the motor functions were reported to be compromised. The techniques required to answer these questions are currently available and could be employed in future studies by these authors or other investigators in the field.
Nevertheless, this study has broad implications regarding the role of the orexin system in the brain under physiological and pathological conditions. First, these experiments confirm the innervation of the LVN by the orexin system in the LH/periforncal area, specifically to the critical neurons in the LVN that are responsible for the control of posture and motor function proposed by previous studies (Cutler et al., 1999; Peyron et al., 1998) (Figure 1 ). More importantly, this study provides a novel and crucial piece of evidence to demonstrate the role of this projection in the central control of motor functions. Second, although the authors suggest that their results demonstrate a role of orexin in the control of motor functions independent of its role in promoting wakefulness and arousal, the effects of orexin on neurons in the LVN can still account for compromised vestibular motor functions resulting from insufficient arousal in animals. Third, the most important implication of these findings is that orexin-mediated effects on LVN neurons may not play a substantial role in static or basal motor control, but rather may participate in motor control under substantial motor challenge. The link between the loss of function of the orexin system and narcolepsy is established (Ritchie et al., 2010) ; however, it still remains to be determined how this loss leads to cataplexy (Scammell et al., 2009) . Although the animal models used here are not intended for the study of cataplexy (nor did the loss of motor function or blockade of orexin-mediated effects in the LVN lead to any loss of motor functions similar to cataplexy), this study in its own right may provide a novel view of how impairment of the output from the orexin system leads to cataplexy in diseases and conditions such as narcolepsy.
In summary, there is still a distance to go to identify how the loss of orexin-mediated functions leads to cataplexy, but this study certainly provides new promise toward that end. Several lines of inquiry can be explored. First, to pinpoint the role of the orexin system in motor control mediated by the LVN neurons, it is essential to monitor the activity levels of orexin neurons as these changes in motor functions occur in various animal models including those used in this study. Conversely, it is critical to examine whether the direct activation or silencing of orexin neurons in vivo with optogenetic approaches such as photostimulation with channelrhodopsin-2 (Adamantidis et al., 2007) leads to initiation or interruption of changes in motor functions mediated by the LVN neurons. Next, if the effects mediated by orexin underlie the cataplexy resulting from the loss of function of the orexin system as suggested by this study, it is both essential and intriguing to know whether the mechanisms reported here exist in other brain areas that control motor functions and sensorimotor integration such as the basal ganglia, spinal locomotor circuitry, and so on (El Manira and Kyriakatos, 2010) . Since the blockade of orexin-mediated effects in a single area may lead to just attenuation and not complete loss of motor control as reported here, a prospective study combining multiple brain regions to reveal the role of orexin in cataplexy would be very beneficial. Lastly, it is important to examine the circuitry investigated in this report in animal models of cataplexy and particularly in animals given an infusion of orexin into the LVN or other brain areas to determine if this treatment can rescue or improve the symptoms of cataplexy. The solid line indicates the direct projection of orexin-containing fibers to the LVN. The gray line indicates pathways from the LVN to the LHA, which may be mediated by polysynaptic mechanisms (Katafuchi et al., 1987) . LHA, lateral hypothalamic area; LVN, lateral vestibular nucleus; 3V, the third ventricle; 4V, the fourth ventricle.
